Table S1. Osteoporosis in male thyroid cancer patients compared to matched controls

	Osteoporosis in Thyroid Cancer Patients	Osteoporosis in Controls[a]	OR (95% CI)
	N (%)	N (%)	
Cohort[b]	539 (6.2)	349 (4.0)	1.46 (1.26 - 1.68)
Median Household Income[c]			
<$35,000	60 (5.4)	46 (3.8)	1.0 (ref)
$35,000 - $59,999	311 (6.1)	212 (4.0)	1.11 (0.89 - 1.39)
≥ $60,000	168 (6.9)	91 (4.3)	1.28 (1.00 - 1.64)
Charlson/Deyo Comorbidity Score			
0	257 (5.3)	199 (3.1)	1.0 (ref)
1	81 (7.3)	38 (4.6)	1.49 (1.19 - 1.86)
≥ 2	201 (7.5)	112 (7.5)	1.74 (1.48 - 2.04)
Androgen Use			
No	495 (6.2)	333 (4.0)	1.0 (ref)
Yes	44 (6.4)	16 (4.0)	1.02 (0.77 - 1.36)

[a] Cohorts were matched for sex, age according to the date of birth (matched within one year), weight (matched within 5 pounds; reported in kg as mean (standard deviation)), and steroid use.
[b] Reference group is controls.
[c] Median household income by geographic region.
Abbreviations: OR, odds ratio; CI, confidence interval; ref, reference

Table S2. Fractures in male thyroid cancer patients compared to matched controls

	Fractures in Thyroid Cancer Patients	Fractures in Controls[a]	OR (95% CI)
	N (%)	N (%)	
Cohort[b]	212 (2,4)	241 (2.8)	0.70 (0.58 - 0.85)
Median Household Income[c]			
<$35,000	27 (2.4)	39 (3.2)	1.0 (ref)
$35,000 - $59,999	130 (2.5)	143 (2.7)	0.98 (0.74 - 1.30)
≥ $60,000	55 (2.3)	59 (2.8)	0.99 (0.72 - 1.37)
Charlson/Deyo Comorbidity Score			
0	60 (1.2)	106 (1.7)	1.0 (ref)
1	37 (3.4)	36 (4.4)	2.73 (2.04 - 3.65)
≥ 2	115 (4.3)	99 (6.6)	3.75 (3.02- 4.67)
Androgen Use			
No	198 (2.5)	235 (2.8)	1.0 (ref)
Yes	14 (2.0)	6 (1.5)	0.66 (0.41 - 1.05)

[a] Cohorts were matched for sex, age according to the date of birth (matched within one year), weight (matched within 5 pounds; reported in kg as mean (standard deviation)), and steroid use.
[b] Reference group is controls.
[c] Median household income by geographic region.
Abbreviations: OR, odds ratio; CI, confidence interval; ref, reference